CSL’s biggest manufacturing investment reaches milestone
Vaccine company CSL Seqirus has announced the ‘topping out’ of the construction of its biggest investment project, its new state-of-the-art manufacturing facility in Melbourne (pictured). The facility will use innovative technology to produce seasonal and pandemic cell-based influenza vaccines, CSL Seqirus’ vaccine adjuvant technology (MF59), the world’s only approved human vaccine for Q fever and…
Details